UNSPSC 51172176: Moxaverine hydrochloride

This classification denotes an antispasmotic agent C20H21NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6R0I0E99CN, chemically known as 1-benzyl-6,7-dimethoxy-3-ethylisoquinoline hydrochloride, but more generally known as moxaverine hydrochloride, which bears US NIH Compound Identifier 70881. European Medicines Agency schedules Moxaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03341MIG.

Most nations, for tariff and trade purposes, schedule moxaverine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, MOXAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCC1CC2CC(C(CC2C(N1)CC3CCCCC3)OC)OC.CL.

UNSPSC 51172176 Moxaverine hydrochloride is a Commodity code that maps to pharmaceutical procurement across state and local health agencies, correctional systems, and cooperative purchasing consortia, though the recent state and local opportunities tagged under this code do not consistently reflect the specific active pharmaceutical ingredient or single-drug focus the code nominally suggests. State and local governments are procuring drug testing services, direct-to-manufacturer prescription fulfillment programs, and multi-source generic pharmaceuticals through this code family. The issuing bodies include county criminal justice departments, state health commissions, and multi-state cooperative purchasing alliances such as MMCAP. Work ranges from specimen collection and laboratory analysis services supporting offender supervision and corrections to broader pharmacy benefit programs and generic pharmaceutical supply agreements that span multiple state jurisdictions.

Collin County Community Supervision and Corrections Department in Texas solicited offender specimen collection and drug testing services via RFP 2026-327, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026 with three optional one-year renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (due April 3, 2026) to gather vendor capability information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. Recent activity clusters in Texas and Minnesota, with cross-jurisdictional reach through MMCAP's multi-state cooperative vehicle.